Skip to main content
Erschienen in: Clinical and Translational Oncology 9/2019

19.02.2019 | Research Article

Current management of breakthrough cancer pain according to physicians from pain units in Spain

verfasst von: F. V. Estévez, Mª D. L. Alarcón, V. Mayoral, M. de Madariaga, C. Margarit, J. A. Duran, J. M. T. Martín-Arroyo, A. Carregal, Grupo de trabajo de dolor oncológico of the SED (Sociedad Española de Dolor)

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Current evidence suggests the need to improve the management of breakthrough cancer pain (BTcP). For this reason, we aimed to assess the opinion of a panel of experts composed exclusively of physicians from pain units, who play a major role in BTcP diagnosis and treatment, regarding the key aspects of BTcP management.

Methods

An ad hoc questionnaire was developed to collect real-world data on the management of BTcP. The questionnaire had 5 parts: (a) organizational aspects of pain units (n = 12), (b) definition and diagnosis (n = 3), (c) screening (n = 3), (d) treatment (n = 8), and (e) follow-up (n = 7).

Results

A total of 89 pain-unit physicians from 13 different Spanish regions were polled. Most of them agreed on the traditional definition of BTcP (78.9%) and the key features of BTcP (92.1%). However, only 30.3% of participants used the Davies’ algorithm for BTcP diagnosis. Respondents preferred to prescribe rapid-onset opioids [mean 77.0% (SD 26.7%)], and most recommended transmucosal fentanyl formulations as the first option for BTcP. There was also considerable agreement (77.5%) on the need for early follow-up (48–72 h) after treatment initiation. Finally, 65.2% of participants believed that more than 10% of their patients underused rapid-onset opioids.

Conclusions

There was broad agreement among pain experts on many important areas of BTcP management, except for the diagnostic method. Pain-unit physicians suggest that rapid-onset opioids may be underused by BTcP patients in Spain, an important issue that need to be evaluated in future studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–81.CrossRefPubMed Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–81.CrossRefPubMed
2.
Zurück zum Zitat Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great B, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–8. https://doi.org/10.1016/j.ejpain.2008.06.014.CrossRefPubMed Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great B, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–8. https://​doi.​org/​10.​1016/​j.​ejpain.​2008.​06.​014.CrossRefPubMed
8.
Zurück zum Zitat Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1–2):129–34.CrossRefPubMed Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1–2):129–34.CrossRefPubMed
30.
Zurück zum Zitat Kaye AD, Jones MR, Kaye AM, Ripoll JG, Galan V, Beakley BD, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Phys. 2017;20(2S):S93–S109. Kaye AD, Jones MR, Kaye AM, Ripoll JG, Galan V, Beakley BD, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Phys. 2017;20(2S):S93–S109.
Metadaten
Titel
Current management of breakthrough cancer pain according to physicians from pain units in Spain
verfasst von
F. V. Estévez
Mª D. L. Alarcón
V. Mayoral
M. de Madariaga
C. Margarit
J. A. Duran
J. M. T. Martín-Arroyo
A. Carregal
Grupo de trabajo de dolor oncológico of the SED (Sociedad Española de Dolor)
Publikationsdatum
19.02.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 9/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02044-8

Weitere Artikel der Ausgabe 9/2019

Clinical and Translational Oncology 9/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.